A detailed history of Abrdn PLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Abrdn PLC holds 269,782 shares of AKRO stock, worth $13.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
269,782
Previous 123,358 118.7%
Holding current value
$13.9 Million
Previous $3.54 Million 112.07%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 24, 2025

BUY
$26.75 - $35.28 $3.92 Million - $5.17 Million
146,424 Added 118.7%
269,782 $7.51 Million
Q3 2024

Oct 24, 2024

SELL
$21.45 - $29.34 $1.63 Million - $2.23 Million
-75,879 Reduced 38.08%
123,358 $3.54 Million
Q1 2024

May 08, 2024

BUY
$17.76 - $31.18 $2.27 Million - $3.98 Million
127,695 Added 178.49%
199,237 $5.03 Million
Q4 2023

Jan 31, 2024

BUY
$11.38 - $50.33 $814,147 - $3.6 Million
71,542 New
71,542 $1.67 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $2.39B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Abrdn PLC Portfolio

Follow Abrdn PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.